Immunomodulation, part II: granulocyte colony-stimulating factors

Area of Science:

• Neonatal Medicine
• Pediatric Infectious Diseases
• Hematology

Background:

• Recombinant human granulocyte colony-stimulating factors (rhG-CSF and rhGM-CSF) are being investigated for their potential role in managing neonatal sepsis.
• While generally considered safe, their efficacy in treating or preventing sepsis in preterm infants remains unclear.
• Current evidence does not strongly support their use in non-neutropenic septic infants.

Discussion:

• Adequately powered, randomized controlled trials are essential to determine the efficacy of rhG-CSF and rhGM-CSF as adjunctive therapies in neutropenic infants with sepsis.
• Further research is needed to establish clear guidelines for the use of these agents in specific neonatal populations.
• The potential for long-term neurologic sequelae from neonatal infections necessitates comprehensive follow-up in all relevant studies.

Key Insights:

• The utility of rhG-CSF and rhGM-CSF in neonatal sepsis is uncertain, particularly in non-neutropenic infants.
• High-quality clinical trials focusing on neutropenic preterm infants are required to assess these growth factors' effectiveness.
• Long-term neurodevelopmental follow-up is crucial for evaluating the complete impact of neonatal infections and their treatments.

Outlook:

• A UK study is evaluating prophylactic GM-CSF for infants at high risk of postnatal neutropenia.
• Future research should prioritize robust trial designs with extended follow-up periods.
• Subsequent research in this series will examine the role of intravenous immunoglobulins in neonatal sepsis prevention and treatment.